A Rare Occurrence of Hyperkalemia Following Remdesivir: A Case Series

##plugins.themes.bootstrap3.article.main##

  •   Harsh H. Patel

  •   Sapna D. Gupta

  •   Supriya D. Malhotra

Abstract

Remdesivir is a nucleoside analog with broad-spectrum antiviral activity against several viruses such as respiratory syncytial virus, Nipah virus, Ebola virus (EBOV), Middle East respiratory syndrome (MERS-CoV), and Severe Acute respiratory Syndrome Coronavirus-1 (SARS-CoV-1). Remdesivir has been used in moderate to severe COVID-19 during the pandemic. Remdesivir is associated with various adverse drug reactions like serum transaminase elevation, nausea, diarrhea, vomiting, poor appetite, gastroparesis, pneumothorax, hypotension, hematuria etc. It has been rarely associated with hyperkalemia. We have reported 3 cases of hyperkalemia following Remdesivir use. In all 3 cases, patients did not have any renal pathology or history of alcohol consumption. Patients were not taking any concurrent medication which increases serum potassium levels with such characteristics seen in our cases. Temporal association was present between hyperkalemia and initiation of Remdesivir in all cases described. Hence, it is very important to be vigilant while prescribing Remdesivir in COVID-19.


Keywords: Adverse drug reaction, Hyperkalemia, Rare occurrence, Remdesivir

References

R. T. Eastman, J. S. Roth, K. R. Brimacombe, A. Simeonov, M. Shen, S. Patnaik and M. D. Hall, “Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19.” ACS central Science 4;6(5):672-83, 2020.

M. K. Lo, R. Jordan and A. Arvey, “GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses.” Sci Rep 7:43395, 2017.

T. P. Sheahan, A. C. Sims and R. L. Graham, “Broad-spectrum antiviral GS5734 inhibits both epidemic and zoonotic coronaviruses.” Sci Transl Med 9(396), 2017.

M. L. Agostini, E. L. Andres, A. C. Sims, R. L. Graham, T. P. Sheahan, X. Lu, E. C. Smith, J. B. Case, J. Y. Feng, R. Jordan and A. S. Ray, “Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease.” MBio 6;9(2):e00221-18, 2018.

J. S. Morse, T. Lalonde, S. Xu and W. R. Liu, “Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV.” Chembiochem 21(5):730-8, 2020.

Q. Fan, B. Zhang, J. Ma and S. Zhang, “Safety profile of the antiviral drug remdesivir: An update.” Biomedicine & Pharmacotherapy 130:110532, 2020.

C. Ben Salem, A. Badreddine, N. Fathallah, R. Slim and H. Hmouda “Drug-induced hyperkalemia.” Drug Saf 37(9):677-92, 2014.

C. P. Kovesdy, “Management of hyperkalemia in chronic kidney disease.” Nat Rev Nephrol 10(11), 653, 2014.

Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 121304016, Remdesivir; [cited 2021 June 6]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir/.

H. Pan, R. Peto, Q. A. Karim, M. Alejandria, A. M. H. Restrepo, C. H. Garcia and M. P. Preziosi, “Others, Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results.” medRxiv 2020.

J. Beigel, K. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil and C. H. Lane, “Remdesivir for the treatment of Covid-19—final report.” N Engl J Med 2020.

##plugins.themes.bootstrap3.article.details##

How to Cite
Patel, H. H., Gupta, S. D., & Malhotra, S. D. (2021). A Rare Occurrence of Hyperkalemia Following Remdesivir: A Case Series. European Journal of Clinical Medicine, 2(5), 4–6. https://doi.org/10.24018/clinicmed.2021.2.5.121